Welcome to our dedicated page for Barrick Mining Corporation news (Ticker: B), a resource for investors and traders seeking the latest updates and insights on Barrick Mining Corporation stock.
Barnes Group Inc. (NYSE: B) maintains its position as a global leader in precision industrial technologies and aerospace solutions. This news hub provides investors and industry professionals with essential updates on corporate developments, financial performance, and strategic initiatives.
Access timely updates spanning earnings announcements, product innovations, and operational milestones. Our curated collection features official press releases alongside market analysis relevant to Barnes Grp's industrial and aerospace segments.
Key coverage areas include manufacturing advancements in transportation systems, aerospace component developments, and strategic partnerships across global markets. The repository serves as a reliable resource for understanding the company's impact on sectors ranging from healthcare infrastructure to defense technologies.
Bookmark this page for streamlined access to Barnes Grp's latest financial disclosures and operational updates. Regularly refreshed content ensures stakeholders maintain current awareness of this engineering leader's market position and technological contributions.
Hexagon AB (HEXA B) has announced plans to separate its Asset Lifecycle Intelligence (ALI) division and related businesses through a Lex Asea distribution to shareholders, with an expected listing on a U.S. national securities exchange in early 2026. The new company ('NewCo') will include the expanded perimeter of Safety, Infrastructure & Geospatial (SIG) division, ETQ business, and Bricsys business.
NewCo will operate as a standalone software and SaaS company, led by Mattias Stenberg. As of December 31, 2024, NewCo had approximately 7,200 employees and revenues of EUR 1,448 million with an adjusted operating margin of 31%. The remaining Hexagon business will retain approximately 17,600 employees with revenues of EUR 3,953 million and an adjusted operating margin of 29%.
The separation process is subject to stakeholder approval, regulatory consents, and other conditions, with completion targeted for first half of 2026. A temporary Swedish Depository Receipt programme will be established via Nasdaq Stockholm to facilitate the transition.
BioArctic AB (NASDAQ: BIOA B) announced that Australia's Therapeutic Goods Administration (TGA) has declined to approve lecanemab for early Alzheimer's disease treatment. The TGA rejected both the initial application in October 2024 and a December 2024 reconsideration request that proposed limiting the treatment to ApoE4 noncarriers and heterozygotes.
The TGA suggested a narrower indication for ApoE4 noncarriers only, citing safety concerns for ApoE4 heterozygotes. Despite Eisai's proposal for treating heterozygotes in specialist centers under expert supervision, the TGA maintained its rejection.
This decision affects approximately 411,000 people living with dementia in Australia as of 2023, with this number projected to reach 849,000 by 2058. Lecanemab, which works by clearing toxic Aβ protofibrils and plaques, has already received approval in 11 markets including the US, Japan, China, and the UK, with pending applications in the EU and 17 other regions.
BioArctic AB (BIOA B) announced that the European Medicines Agency's CHMP has reaffirmed its positive opinion for lecanemab (Leqembi®) in early Alzheimer's disease, originally adopted in November 2024. This follows the European Commission's January 2025 request to review additional safety information and risk minimization measures clarity.
Leqembi, an anti-Aβ monoclonal antibody targeting toxic protofibrils and Aβ plaques, is already approved in the US, Japan, China, and Great Britain. If approved by the EC, the marketing authorization will extend to all 27 EU member states, Iceland, Liechtenstein, and Norway.
BioArctic AB announced the completion of its global license agreement with Bristol Myers Squibb after receiving U.S. Federal Trade Commission clearance. The agreement, initially announced on December 19, 2024, grants Bristol Myers Squibb worldwide development and commercialization rights for BAN1503 and BAN2803, part of BioArctic's PyroGlutamate-amyloid-beta antibody program for Alzheimer's disease.
The deal includes a USD 100 million upfront payment to BioArctic, potential milestone payments up to USD 1.25 billion, and tiered low double-digit royalties on global sales. BioArctic retains Nordic region co-commercialization rights and maintains rights to its BrainTransporter platform technology for other applications.
The PyroGlu-Aβ antibody program targets a specific modified form of amyloid-beta that tends to aggregate and cause Alzheimer's symptoms. BAN2803 incorporates BioArctic's BrainTransporter technology, marking the first license agreement utilizing this platform.
BioArctic AB (Nasdaq Stockholm: BIOA B) announced that its partner Eisai has achieved the first sales milestone for Leqembi®, reaching €200 million in sales during Eisai's fiscal year 2024 (April 2024 - March 2025). This achievement triggers a €10 million milestone payment to BioArctic.
Leqembi, an antibody developed through collaboration between BioArctic and Eisai, originated from Professor Lars Lannfelt's research on the Arctic mutation in Alzheimer's disease. While Eisai manages clinical development, market approval applications, and global commercialization, BioArctic retains rights to commercialize Leqembi in the Nordic region jointly with Eisai, with preparations for regional commercialization currently underway.
SDI Presence has announced a strategic partnership with Hexagon's Safety, Infrastructure & Geospatial division to enhance the deployment of public safety dispatching and communication solutions. The collaboration formalizes a decades-long relationship between the companies, focusing on implementing Hexagon's computer-aided dispatch (CAD) systems for emergency response agencies across North America.
SDI will provide implementation, technical support, GIS development, and business analysis services for Hexagon's solutions. The partnership aims to improve emergency response times and situational awareness for first responders. SDI's team includes certified experts in Hexagon technologies and PMI-certified professionals, positioning them as an authorized partner in configuring and optimizing Hexagon's solutions.
ETQ, a Hexagon company, marked significant achievements in Q4 2024, strengthening its position in quality management systems (QMS). The company launched its ETQ Reliance Predictive Quality Analytics solution, powered by AI technology from Acerta Analytics, enabling automated early detection and proactive resolution of manufacturing quality issues.
The quarter saw notable customer expansion across various sectors including heavy industry, manufacturing, food & beverage, electronics, life sciences, and aerospace. New clients included Bray International, CoreWeave, and Koch Ag & Energy Solutions, while existing customers like Cosmo Pharmaceuticals and Keurig Dr Pepper expanded their ETQ Reliance implementation.
ETQ hosted its 2024 ETQ Reliance Customer Conference in Dallas, featuring presentations from leading brands like Hitachi Energy and Kimberly-Clark. The company also conducted its Innovation Excellence Awards, with RR Donnelley winning for improving environmental health & safety performance through ETQ Reliance.
Crawford & Company (NYSE: CRD-A and CRD-B) has announced its quarterly dividend declaration following the Board of Directors meeting on February 6, 2025. The company will distribute a quarterly dividend of $0.07 per share for both Class A and Class B Common Stock. The dividend will be paid on March 7, 2025, to shareholders who are recorded as stockholders as of the close of business on February 24, 2025.
BioArctic AB (BIOA B) announced that the European Commission has requested the Committee for Medicinal Products for Human Use (CHMP) to address two additional questions regarding lecanemab, their early Alzheimer's disease treatment. Despite receiving a positive CHMP opinion in November 2024, the EC needs clarification on safety information that emerged after the opinion and the clarity of risk minimization measures.
The questions will be discussed at the February 2025 CHMP meeting before a final EC decision. Importantly, the safety profile of lecanemab in clinical practice in the US, Japan, and other markets remains consistent with approved labels, with no new safety signals identified. Eisai, BioArctic's partner, believes existing information is sufficient to address the EC's concerns.
Leqembi, developed through collaboration between BioArctic and Eisai, originated from Professor Lars Lannfelt's research on the Arctic mutation in Alzheimer's disease. While Eisai leads clinical development and commercialization, BioArctic maintains Nordic region commercialization rights alongside Eisai.
Barnes Group (NYSE: B) has completed its previously announced acquisition by Apollo Funds in an all-cash transaction with a total enterprise value of approximately $3.6 billion. Under the terms of the agreement, Barnes shareholders will receive $47.50 per share in cash.
The transaction, announced on October 7, 2024, and approved by Barnes shareholders on January 9, 2025, marks a significant milestone for the global provider of engineered products and industrial technologies. Following the completion, Barnes' common stock has ceased trading and will be delisted from the NYSE.
The acquisition aims to accelerate Barnes' transformation strategy, enhance capabilities, and broaden product offerings. Apollo sees significant potential in Barnes' aerospace and industrial sectors portfolio, particularly noting the company's positioning to benefit from robust aerospace demand trends.
FAQ
What is the current stock price of Barrick Mining Corporation (B)?
What is the market cap of Barrick Mining Corporation (B)?
